COMPASS Pathways Overview
- Founded
-
2016
- Status
-
Public
- Employees
-
116
- Stock Symbol
-
5Y6
- Investments
-
2
- Share Price
-
$18.42
- (As of Friday Closing)
COMPASS Pathways General Information
Description
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Contact Information
Website
www.compasspathways.com
Formerly Known As
COMPASS Pathways Technologies
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Therapeutic Devices
Stock Exchange
BER
Primary Office
- 3rd Floor, 1 Ashley Road
- Cheshire
- Altrincham WA14 2DT
- England, United Kingdom
COMPASS Pathways Timeline
COMPASS Pathways Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $18.42 | $17.41 | $6.71 - $49.74 | $780M | 42.5M | -$1.99 |
COMPASS Pathways Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 219,278 | 628,300 | 1,515,216 | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (83,104) | (71,368) | (60,190) | (19,534) |
| Net Income | (83,707) | (71,742) | (60,334) | (19,612) |
| Total Assets | 238,636 | 300,898 | 203,456 | 32,389 |
| Total Debt | 2,987 | 3,614 | 0 | 21,089 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
COMPASS Pathways Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
COMPASS Pathways Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
COMPASS Pathways Patents
COMPASS Pathways Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020258086-A1 | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation | Pending | 17-Apr-2019 | 0000000000 | |
| CA-3138008-A1 | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation | Pending | 17-Apr-2019 | 0000000000 | |
| AU-2020259406-A1 | Treatment of depression and other various disorders with psilocybin | Pending | 17-Apr-2019 | 0000000000 | |
| CA-3138094-A1 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | Pending | 17-Apr-2019 | 0000000000 | |
| EP-3955936-A1 | Treatment of depression and other various disorders with psilocybin | Pending | 17-Apr-2019 | A61K31/675 |
COMPASS Pathways Executive Team (15)
COMPASS Pathways Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Annalisa Jenkins | COMPASS Pathways | Board Member | 000 0000 |
| David Norton | COMPASS Pathways | Board Member | 000 0000 |
| Ekaterina Malievskaia MD | COMPASS Pathways | Founder & Board Member | 000 0000 |
| Florian Brand | Self | Board Member | 000 0000 |
| George Goldsmith | COMPASS Pathways | Chairman | 000 0000 |
COMPASS Pathways Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
COMPASS Pathways Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
COMPASS Pathways Investments (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000 | 14-Sep-2021 | 000000000 | Buildings and Property | 0000 0000 | |
| Delix Therapeutics | 06-Mar-2020 | Corporate | 00000 | Drug Discovery |